Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma LSE:AMYT London Ordinary Share GB00BDD1LS57 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 16.85p 28,916 08:00:00
Bid Price Offer Price High Price Low Price Open Price
16.70p 17.00p 16.85p 16.85p 16.85p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 11.4 -23.2 -10.4 - 36.54

Amryt Pharma (AMYT) Latest News

More Amryt Pharma News
Amryt Pharma Takeover Rumours

Amryt Pharma (AMYT) Share Charts

1 Year Amryt Pharma Chart

1 Year Amryt Pharma Chart

1 Month Amryt Pharma Chart

1 Month Amryt Pharma Chart

Intraday Amryt Pharma Chart

Intraday Amryt Pharma Chart

Amryt Pharma (AMYT) Discussions and Chat

Amryt Pharma Forums and Chat

Date Time Title Posts
24/5/201808:22Amryt Pharma2,892
27/3/201708:19Amryt Pharma108
21/4/201610:07AMYT1
21/4/201610:04Amryt Pharma2

Add a New Thread

Amryt Pharma (AMYT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07:47:0716.7013,7482,295.92O
07:27:2516.7010,0001,670.00O
07:03:0616.895,168872.88O
2018-05-23 14:49:1316.707512.53O
2018-05-23 13:52:3116.892,291386.95O
View all Amryt Pharma trades in real-time

Amryt Pharma (AMYT) Top Chat Posts

DateSubject
24/5/2018
09:20
Amryt Pharma Daily Update: Amryt Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AMYT. The last closing price for Amryt Pharma was 16.85p.
Amryt Pharma has a 4 week average price of 16.75p and a 12 week average price of 16.75p.
The 1 year high share price is 28.75p while the 1 year low share price is currently 16.75p.
There are currently 216,839,632 shares in issue and the average daily traded volume is 140,482 shares. The market capitalisation of Amryt Pharma is £36,537,477.99.
19/5/2018
14:48
papillon: Bronxville Posts: 243 Off Topic Opinion: No Opinion Price: 17.35 RE: Friel's buy...32p in today's m..Today 00:00 £692,000 in Friels cold hard cash spent. Why is he selling at .17 now? Why Open Orphan? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> True, Bronxville, but what you're CONVENIENTLY FORGETTING is he only bought 2.6m AMYT shares @ 32p (via the 20.8m FAST shares he bought @ 4p) OUT OF A TOTAL of 33m AMYT shares he held until he sold 8.38m recently @ 17p. It's easy enough to check, but I suspect that FRIEL'S AVERAGE COST per AMYT share was MUCH LESS THAN 10p, Bronxville, since many of his 33m AMYT shares were acquired for NEGLIGABLE (or ZERO) cost due to his being one of the founders of AMYT. HENCE, Bronxville, I suspect Friel could sell ALL of his 33m shares @ 17p and still make a magnificent profit. I wouldn't be surprised if he doubled his money (at least) @ 17p compared to his AVERAGE buying price. You need to stop prattling on about the shares Friel bought @ the equivalent of 32p because it was only a small percentage of his 33m shares and the AVERAGE cost to him would likely be less than 10p. Lots of LOVE, papillon! :-) PS. I see Bronxville has filtered me. Not that I'm worried as I don't post on the lse bb's. PPS. Bronxville is digging up as much dirt as he can, even if the link to AMYT is tenuous. Good luck to him, because no one will take the slightest notice of him. NEWS drives share prices, not anonymous posters on bb's. Will the AMYT share price go towards £1, or 1p, during the next 12 months? IT ALL DEPENDS ON THE NEWS AMYT RELEASES AND WHETHER INVESTORS BELIEVE THAT NEWS, OR NOT. I can GUARANTEE that Bronxville will have absolutely NO influence on the direction of the AMYT share price over the next 12 months. Bronxville is SORE with Friel & AMYT because he bought FAST shares at a high price and consequently LOST a lot of his money when he bailed out of AMYT. That's understandable. He's a VERY SORE LOSER!
18/5/2018
23:13
papillon: Bronxville Posts: 239 Off Topic Opinion: No Opinion Price: 17.35 A little memory loss Paps Today 21:35 11/8/2015 21:37 papillon: Friel could be feathering his nest, Asturius101, but he's showing a funny old way of going about it since he paid almost double the price recently to acquire over 18m FAST shares (he paid 4p per share when the then share price was 2.25p)!! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Sorry Bronxville. There's NOTHING wrong with my memory! However there is something wrong with yours! You're NOT using your little grey cells. Cathal Friel had just over 33m AMYT shares. He has sold 8.38m and now has circa 24.67m. http://uk.advfn.com/stock-market/london/amryt-pharma-AMYT/share-news/Amryt-Pharma-PLC-Holdings-in-Company-and-Lock-in-a/77363966 Cathal Friel ended up with 39.75m shares in FAST in July 2015 after buying circa 20.85m FAST shares @ 4p (4p was then a very large percentage premium to the then quoted FAST sp). He bought those shares to stop the owners from blocking his bid to turn FAST into a biotech via an RTO. He had to pay way over the odds. I know all this because I bought my first FAST shares early in 2015 because of the large percentage discount that the shares were trading at compared to their cash. http://uk.advfn.com/stock-market/london/fastnet-equity-FAST/share-news/Fastnet-Oil-Gas-PLC-Director-PDMR-Shareholding/67572254 http://uk.advfn.com/stock-market/london/fastnet-equity-FAST/share-news/Fastnet-Oil-Gas-PLC-Director-PDMR-Shareholding/67475086 If you divide those 20.85m FAST shares by 8 you get the the equivalent number of AMYT shares that, in practice, Friel paid 32p for. That works out at circa 2.6m AMYT shares that, in effect, Friel paid 32p for. Yet until the start of this month Friel had just over 33m AMYT shares. Hence the AMYT shares he paid the equivalent of 32p for was less than 10% of his total holding!! Yet you, Bronxville, in your posts like to give the impression that all of Friel's AMYT shares cost the equivalent of 32p. WHY, is the question I ask? Is it because your memory is failing, or are you deliberately muddying the waters by giving a false impression? Even if you take the total number of FAST shares that Friel held (39.75m) and then convert them into AMYT shares (divide by 8) you get circa 5m AMYT shares. Yet Friel had just over 33m AMYT shares. Hence the total FAST shares held by Friel when converted into AMYT shares only comprised around 15% of his total holding in AMYT shares. In other words, Einstein (sorry, Bronxville) circa 28m of Friel's total holding of circa 33m AMYT shares (around 85%) had NO connection with his holding in FAST. So, in effect, Cathal Friel has sold 8.38m AMYT shares @ 17p from the 28m he acquired directly in AMYT (not via FAST). Some of those 28m shares were founders shares (and were no doubt acquired at no, or negliable, cost), whilst the remainder were acquired via the original placing. However members of the "concert party" (of which Friel was obviously one) did NOT pay 24p for their shares. They got their shares at a sizeable discount. Circa 16p was the price they paid. So by selling 8.38m AMYT shares @ 17p Cathal Friel has still made a profit (if the shares he sold could be considered to be "founders" shares then he made almost all profit because they were acquired at no, or negligable, cost to him). Presumably when he comes to sell his remaining 24.67m shares he will hope to make another profit. If the AMYT share price is above 32p when he next sells some (in 12 months time) he will definitely make a profit on them!!. :-) PS. You really must start posting the whole story, Bronxville and not just that part of the story that suits your agenda. You asked JimbobTechstock "You wouldn't happen to know (Cathal) personally would you." The funny thing is I was thinking of asking you the same question, but about Joe Wiley! LOL. I have wondered if you knew him and had a grudge against him. :-)
16/4/2018
15:47
papillon: "Don't worry, it'll be an insignificant amount!" Glad to hear that, greendragon. :-). Regarding my holding in AMYT, I'll see what happens this week regarding the newsflow and share price, then I'll make a decision on what to do with my 27,215 shares. What to do with my core holding (20k) and the 7,215 I bought recently because the share price was resting on, or near, strong support. Big news is around 6 months away (AP101 interim results) unless there is another Lojuxta type deal announced in the meantime and how likely is that? ATB. PS Weather forecast looking good for the rest of the week. Hoping that the virus that has been lingering on for the last week finally decides to sling it's hook and I can get out and do some gardening; My garden needs some TLC at the moment and I'm getting fed up of moping around and posting on advfn bb's out of boredom! :-)
04/4/2018
14:03
sidam: This is a bit long, but I hope it helps. Since the trading statement, I have undertaken some more research, following which I have concluded that some of the postings on this thread include misunderstandings. So I thought I might give you my take. You will realise I am a bull (I hope not in a china shop). Let us start with the comments on the Amicus data. It appears to me that some commentators have assumed that there was a hidden agenda and that Amicus only gave the information on the understanding or agreement that they would have the marketing rights to AP101 for EB (AP101/EB) in the US. I consider that assumption to be wrong. Management are still indicating that they will enter that market directly. There are only some 20 sites and management considers that they will need only 8 people on the road to cover those. Their budget is $200,000 per employee. The change in the trial to exclude simplex and its possible effects on the level of projected sales. Management’s original guidance of projected peak sales of AP101/EB was €500m. This assumed that the Korblisa trial was successful and entered the market. Management did not change that guidance following the failure of that trial. EB simplex patients account for well over 50% of all EB patients, but they were projected to account for only 20% of sales. Assuming the AP101 trial is successful, unless the labelling specifically excludes simplex patients, they could still be prescribed the product. Furthermore without Korblisa it is possible that peak sales would be significantly higher than originally projected. I am still assuming peak sales of €500m. On that basis, I think the share price could, given time, reach or exceed £2 in the longer term - not now. If anyone wants to know my reasoning, please ask. I am however surprised that there has been so little comment on AP101 for other indications. Although one poster did indicate their view that this would reduce the price of the product. That comment is, I am convinced, wrong. The company has said that these are unmet needs and that they would apply for Orphan Drug Designation for these additional indications. Management has given guidance that the anticipated selling price would be similar to that for EB and that the potential market could be as large. The cost of selling would be higher than for EB as there will be many more sites – every major hospital rather than 35 centres in the EU and 20 in the US. Management also indicated that current EU marketing authorisations could cover some indications. Furthermore some product is being released on compassionate grounds. I understand that Management considers that we could know some of this as early as the interims, which, last year, were in September. If potential sales were €500m, this would also be an extremely valuable product and the risks may be much lower because of existing marketing authorities. So the overall risks have been reduced and the potential increased. The safety play would be to wait until the interims, but I would hope the price would be much higher by then as the news is more widely distributed and understood by the market. The brokers comment on the trading statement was very short and did not go into real detail. I would expect a major note after the final results. That could drive the share price. If anyone is going to share society (I am not), could they clarify some of these points and post a comment.
23/2/2018
19:52
diamondstar1: Greendragon.... I think the share price slide over past 6 months has been due to a combination of factors. One of them being the fact that Amryt was formed from the reverse takeover of Fastnet. This was good, for example, for tax purposes. But legacy Fastnet shareholders perhaps do not fully appreciate the nuances of pharmaceutical drug development. I sense general discontent from shareholders, who interpret every action of the company negatively. For example, when the new Regulatory Head was announced recently, the immediate response was, “too many mouths to feed”. In reality, getting a regulatory person on board is a very positive message for me - as I know that preparation for a regulatory filing (eg with FDA or EMA) takes at least 1 year. Another reason for the share price slide, I believe, is that some people are simply throwing in the towel, as the share price drops, and stop losses are met. These people may have bought on share recommendations from newspapers, and may not again fully understand Amryt as a company. Anyway, thats my two cents regarding the share price drop.... I myself will be holding on tightly to my Amryt shares!!
12/12/2017
17:09
papillon: Bronxville Posts: 62 Off Topic Opinion: No Opinion Price: 20.125 RE: Wiley,Nealon Today 15:50 Yep the market is on to the sleezy antics of this management team. Options should have been at .30 cents.. Wiley basically just gave himself a £400 thousand bonus! For What? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> How has Wiley given himself a £400k bonus, Bronxville? Stop spouting unadultered rubbish. He HASN'T been given 2.061m shares. He's been given OPTIONS to acquire 2.061m shares. BIG DIFFERENCE. For all we know the AMYT share price will stay below the 20.12p subscription price (hope it doesn't, LOL) in which case he wont ever exercise that option to buy. This is AIM and AMYT still has a £55m Mkt Cap. There is NO guarantee that AP101 will be successful and there is NO guarantee that those who know how the phase 3 trial is progressing wont take advantage of that knowledge by selling, shorting, in the market. Not saying that will happen, but hey, who knows? I'm not against options per se, but the option price should have been much higher than the actual 20.12p. Perhaps 40p. That would have been an incentive. EDIT: For your information, Bronxville, Wiley will have received a £400k bonus from the BoD if the AMYT share price reaches 40p. Will it? Who can tell? I hope so, but I wouldn't bet my house on it happening. This is AIM after all and AMYT is very spculative. I've had a £4k gamble on AMYT, which I might push up to a maximum of £5k, but that's not definite. I definitely wouldn't go above £5k. I'm not rich enough to gamble more than £5k; after all I wouldn't bet £5k on a horse race, but some do!
14/11/2017
16:54
papillon: Bronxville Posts: 21 Off Topic Opinion: No Opinion Price: 18.125 RE: Slide Today 15:12 Management are a disgrace... I have never seen so many rookie mistakes starting with the share price drop from .24 in the original reverse merger.Not to mention blatently misleading shareholders on companies valuation. Ineptitude!! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> LOL. LOL. Bronxville is the disgrace! Management are doing their job. The share price is dictated by short term traders! The job of management is to open up new markets for Lojuxta and progress the trials for AP101 & AP102. They seem to be doing that. Investors, especially short term traders, dictate the share price!!!!!!!!!! Obviously the recent placing was bad news for the AMYT share price in the short term. Why the BoD decided that the time was right to raise more cash is open to question. I don't think it affects AMYT prospects in the medium & longer term; Lojuxta sales and the trial results will determine the AMYT share price in the medium & longer term.
03/7/2017
15:49
papillon: An example of what bad news can do to a share price is UJO today. The share price has been quite bullish, on good volume, over the last few days, in anticipation of a good result from a N. Lincclnshire planning application, but bad news has just been issued and the UJO share price has collapsed! Confirmation, if any was needed, that news drives share prices.
04/11/2016
16:22
papillon: It's proving to be a very slow death for the AMYT share price in the continuing absence of good news (in fact any news!) from the company. I seem to remember the intraday low was around 14-14.25p back in early July. Will a retest of that low encourage bottom fishing buyers again, or will the AMYT share price continue it's descent into oblivion? Answers on a postcard please! LOL. Is AMYT worth a bottom fishing buy I wonder when it's below 15p?
19/8/2016
19:29
papillon: dingo75 16 Aug'16 - 13:26 - 295 of 302 1 0 papp lol egg on your FACE! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> LOL. I'm always ending up with egg on my face, dingo75. However I still believe we will see a small, short term, fall back in the AMYT share price and then the formation of a bullish Inverse Head & Shoulders. You could be right and I will be proved wrong and end up with egg on my face, but I'm hopeful I will soon be proved right. After all a bullish chart formation, after a period of a falling share price, is often the sign that a significant price reversal and subsequent major share price rise is on the cards. Don't throw any more raw eggs at me just yet, dingo75, but keep them ready! LOL.
Amryt Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180524 08:35:49